- As adjunctive immunotherapy for high-risk neuroblastoma
- Accelerates myeloid recovery and engraftment in patients undergoing bone marrow transplant
- Mobilization for peripheral blood stem cell harvest
- Increase neutrophil recovery in patients receiving myelosuppressive chemotherapy
- Available as 250 mcg/vial lyophilized powder for injection.
- Reconstitute lyophilized powder with 1 mL of SWFI for a final concentration of 250 mcg/mL. Direct the diluent at the side of the vial to prevent foaming. Gently swirl to dissolve. DO NOT SHAKE.
- Stable for 6 hours at room temperature once reconstituted or once diluted for IV infusion.
- Do not shake. Protect from light.
- Keep vials in refrigerator. Do not freeze.
- Solutions Compatible: Albumin and NS only.
- Additives/above cassette Compatible: Do not mix with other drugs or IV solutions.
- Y-site Compatible: Do not run with other drugs or IV solution
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
YES, PREFERRED (less toxicity)
Usual dilution: 250 mcg/mL
|IV Intermittent Infusion||
YES, Do not use an in-line filter when infusing
|IV Continuous Infusion||
If final concentration less than 10 mcg/mL, add albumin 1 mg/mL to prevent adsorption
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- 250 mcg/m2/day subcutaneously x 14 days
- 250 mcg/m2/day subcutaneously x 7 days or as per protocol
- 5 - 10 mcg/kg/day (max 30 mcg/kg/day) or 250 mcg/m2/day subcutaneously x 14 - 21 days
Bone Marrow Transplant:
- 250 mcg/m2/day subcutaneously x 21 days, beginning 2-4 hours post BMT
- Flu-like Syndrome: fever, chills, headache, myalgia, bone pain, transient rash, malaise, abdominal cramps, anorexia, nausea
- First Dose Reaction: respiratory distress, hypoxia, hypotension with flushing, syncope, tachycardia (can occur within 3 hours of first dose)
- Urticaria, dyspnea, rigors
- Local reaction
- Anaphylaxis (rare)
- Thromboembolic phenomena (rare)
- Capillary leak syndrome (rare)
- All side effects are worse with IV route
- Do not administer within 24 hours following administration of chemotherapy or 12 hours prior or after radiotherapy
- Hold if WBC greater than 50 x 10 9/L. Resume at 50% dose once WBC is less than 20 x 109/L
- Monitor renal and liver function tests if pre-existing dysfunction
- Concomitant therapy with sargramostim and vincristine in lymphoma patients has resulted in severe peripheral neuropathy, usually localized to the feet
- Concomitant therapy with lithium and sargramostin should be undertaken with caution. Patients receiving lithium and sargramostin should have more frequent monitoring of neutrophil counts.
Federal Drug Association (FDA): Leukine Product Monograph. Accessed 22Nov2019.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103362s5237lbl...